NLRP3 and vasculitis: This mouse model of KD vasculitis has helped establish the critical role of IL-1B in this disease, as blocking the IL-1 pathway either with anakinra or using small-molecule inhibitors of NLRP3, or using mice deficient in Il1a, Il1b, Nlrp3, or Casp1, is the most efficient way to decrease the severity of LCWE-induced KD vasculitis, and is more effective than targeting other proinflammatory mediators (7, 45–47).